bi 1361849
Vaccineexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2017 (NCT03164772)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 1361849
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03164772 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Boehringer Ingelheim, Cancer Research Institute, CureVac AG, Laura & Isaac Perlmutter Cancer Center, Ludwig Institute for Cancer Research, MedImmune, PharmaJet, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 1 | 0 | 1 | 2017 |
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2017 |
| CureVac AG | For profit | 1 | 0 | 1 | 2017 |
| Laura & Isaac Perlmutter Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2017 |
| MedImmune | For profit | 1 | 0 | 1 | 2017 |
| PharmaJet, Inc. | For profit | 1 | 0 | 1 | 2017 |
7 organizations
Page 1 / 1